Author reply
We appreciate the interest of Galvis et al in our paper. Clinically observed incidence of endothelial immune rejection seems to be recognized as the final result of sustained immune rejection. Endothelial immune rejection response is a process from the initial antigen recognition to gradual accumulation and eruption. The period of the first 2 weeks after surgery is primarily regarded as an optimal drug administration timepoint rather than the occurrence time of endothelial rejection. Obviously, prompt and direct achievement of sufficient intraocular drug levels may inhibit the launch of an immune response (Read more...)